Trials / Completed
CompletedNCT00469456
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 265 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine | Memantine 20mg (10mg twice daily) oral administration for 12 weeks |
| DRUG | placebo | Placebo oral administration twice daily for 12 weeks |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-05-04
- Last updated
- 2009-12-24
- Results posted
- 2009-12-07
Locations
25 sites across 3 countries: Australia, New Zealand, South Africa
Source: ClinicalTrials.gov record NCT00469456. Inclusion in this directory is not an endorsement.